1.
单因素分析影响老年SCLC患者生存期的相关因素
Single analysis for survival of the total SCLC in the elderly
| Factor | n (%) | MST (month) | 95%CI (month) | P | |
| SCLC: small cell lung cancer; PS: performance status; ECOG: Eastern Cooperative Oncology Group; EP: etoposide+cisplatin; EC: etoposide+carboplatin; MST: median survival time; LD: limited-stage; ED: extensive-stage. | |||||
| Total | 160 | 12 | 10.6-13.4 | ||
| Sex | Male | 120 (75.0) | 11 | 9.6-12.4 | 0.050 |
| Female | 40 (25.0) | 16 | 14.1-17.9 | ||
| Age (yr) | 65-75 | 135 (84.4) | 12 | 10.2-13.8 | 0.118 |
| ≥75 | 25 (15.6) | 9 | 4.1-13.9 | ||
| PS before treatment (ECOG) | 0 | 14 (8.8) | 23 | 10.1-35.9 | 0.007 |
| 1 | 114 (71.2) | 13 | 11.1-14.9 | ||
| 2 | 26 (16.2) | 11 | 10.1-11.9 | ||
| 3 | 6 (3.8) | 8 | 3.2-12.8 | ||
| The change of PS after treatment (ECOG) | Improve | 71 (44.4) | 13 | 10.1-15.9 | 0.001 |
| Stable | 67 (41.9) | 12 | 10.0-14.0 | ||
| Worsen | 22 (14.7) | 4 | 1.3-6.7 | ||
| Stage | LD | 45 (28.1) | 24 | 18.0-30.0 | < 0.001 |
| ED | 115 (71.9) | 11 | 9.7-12.3 | ||
| Liver | Yes | 29 (18.1) | 7 | 5.0-9.0 | < 0.001 |
| No | 131 (81.9) | 14 | 11.6-16.4 | ||
| Lung | Yes | 42 (26.3) | 11 | 9.3-12.7 | 0.016 |
| No | 118 (73.7) | 13 | 10.1-15.9 | ||
| Brain | Yes | 24 (15.0) | 8 | 6.1-9.9 | 0.001 |
| No | 136 (85.0) | 13 | 10.8-15.2 | ||
| Abdomen | Yes | 32 (20.0) | 10 | 7.8-12.2 | 0.001 |
| No | 128 (80.0) | 13 | 10.4-15.6 | ||
| Bone | Yes | 28 (17.5) | 9 | 6.4-11.6 | 0.001 |
| No | 132 (82.5) | 13 | 9.7-16.3 | ||
| Chemotherapy scheme | EP or EC | 126 (78.8) | 12 | 10.1-13.9 | 0.253 |
| Not EP or EC | 34 (21.2) | 10 | 7.1-12.9 | ||
| Radiotherapy | Yes | 79 (49.4) | 17 | 13.7-20.3 | < 0.001 |
| No | 81 (50.6) | 9 | 7.0-11.0 | ||